Podcast appearances and mentions of Donna H Ryan

Editor's Note: This was recorded prior to Wegovy being approved for cardiovascular disease. View the story here. This podcast episode discussed the impact of celebrity endorsements on trends in weight loss drugs like Ozempic, body image issues, and the role of pharmacists in educating patients on appropriate use of GLP-1 medications for weight management and chronic diseases. Experts Include:  Patricia Mars, MD, owner and medical director of Venus By Mars Cosmetic Surgery and La Paloma Surgery Center; Donna H. Ryan, MD, Professor Emerita at Pennington Biomedical Research Center; and Christina Madison, PharmD, FCCP, AAHIVP, the Public Health Pharmacist. Key Takeaways 1. Celebrities have long shaped cultural ideals around aesthetics and beauty through their own appearance trends. 2. Social media promotion of weight loss journeys using GLP-1 drugs like Ozempic by influencers increased public interest, but also risked unsafe practices without medical oversight. 3. While celebrity disclosure of personal experiences can boost awareness of obesity as a medical condition, it's important for endorsements to encourage safe and supervised use of pharmaceutical therapies. 4. Compounded versions of medications like semaglutide lack proper quality control and approval, posing potential dangers. 5. Pharmacists play a key role in educating patients on appropriate and regulated use of emerging weight loss therapies. References 1. Han SH, Safeek R, Ockerman K, et al. Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthet Surg J. 2023;44(1):60-67. doi:10.1093/asj/sjad211 2. Arillotta D, Floresta G, Guirguis A, et al. GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sci. 2023;13(11):1503. Published 2023 Oct 24. doi:10.3390/brainsci13111503 3. Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13(1):20998. Published 2023 Nov 28. doi:10.1038/s41598-023-48267-2

⁠DozeNews PRIME⁠: as melhores e mais didáticas revisões de cardiologia direto na sua caixa de entrada! Assine agora e tenha acesso à todo material já produzido! - ⁠https://dozeporoito.substack.com/ Nesse episódio, com a ilustre presença de Eduardo Nakamura, da plataforma Endodirect, Mateus Prata e Diandro dissecam TUDO que o cardiologista precisa saber sobre o tratamento medicamentoso da obesidade: desde as diversas opções medicamentosas até o uso correto do Wegovy / Ozempic. Ainda discutimos tópicos sobre o futuro do tratamento da obesidade e o uso de substâncias termogênicas ou anfetaminérgicas para auxiliar na perda de peso. O convidado Edu é médico endocrinologista, com formação inteira pela Escola Paulista de Medicina e é sócio-fundador da plataforma Endodirect, com excelentes conteúdos no instagram e no formato podcast. ERRATA: No minuto (21:40), o estudo SCOUT foi publicado no NEJM, e não no The Lancet Minutagem: Introdução (00:00) Indicações do tratamento farmacológico (06:00) Opções e metas terapêuticas (12:30) Medicações off- label (28:00) Tempo de tratamento (32:00) Análogos GLP-1 (35:00) Manejo efeitos colaterias análogos GLP-1 (42:00) Uso off-label análogo GLP-1 e contra-indicações( 43:30) Novas terapias (49:40) Considerações finais (54:40) Referências: Caroline M. Apovian, Louis J. Aronne, Daniel H. Bessesen, Marie E. McDonnell, M. Hassan Murad, Uberto Pagotto, Donna H. Ryan, Christopher D. Still, Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 2, 1 February 2015, Pages 342–362, https://doi.org/10.1210/jc.2014-3415 ASSOCIAÇÃO BRASILEIRA PARA O ESTUDO DA OBESIDADE E DA SÍNDROME METABÓLICA. Diretrizes brasileiras de obesidade. 4. ed. São Paulo: ABESO, 2016.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

สรุปงานวิจัย “The energy balance model of obesity: beyond calories in, calories out” Kevin D Hall, I Sadaf Farooqi, Jeffery M Friedman, Samuel Klein, Ruth J F Loos, David J Mangelsdorf, Stephen O'Rahilly, Eric Ravussin, Leanne M Redman, Donna H Ryan, John R Speakman, Deirdre K Tobias ตีพิมพ์ใน : The American Journal of Clinical Nutrition วันที่ตีพิมพ์ : 4 กุมภาพันธ์ 2565

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.

Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-term weight-loss success.